Gayane G. Totolyan

Gayane G. Totolyan

Auto-generated profile, based on publicly available information

Gayane G. Totolyan

Department of Hospital Therapy named after Academician G.I. Storozhakov Medical Faculty N.I. Pirogov Russian national research medical university

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2021 in Hepatology and Gastroenterology
Verified
Journal Article
Open access
PDF file
LILyudmila Yu. Ilchenko
Lyudmila Yu. Ilchenko
ИФИ. Г. Федоров
И. Г. Федоров
GTG. G. Totolyan
G. G. Totolyan
АЦА. Г. Цветкова
А. Г. Цветкова
ЕГЕ. Г. Гавриленко
Е. Г. Гавриленко
INIGOR G. NIKITIN
IGOR G. NIKITIN
Background. Enzymopathic jaundices are manifested by intermittent hyperbilirubinemia, no changes in the structure of the liver, no hemolysis, Rh-conflict as well as cholestasis being noted. These jaundices include Crigler-Najjar syndrome type I, Crigler-Najjar syndrome type II and Gilbert's syndrome. They are characterized by an autosomal recessive inheritance due to the presence of mutations and polymorphisms in uridine 5'-diphosphate-glucuronosyltransferase gene (UGT1A1) leading to a decrease of the enzyme activity or to its complete loss. Objective. To demonstrate the peculiarities of diagnosis and treatment of a rare case of hereditary unconjugated hyperbilirubinemia - a combination of Crigler-Najjar syndrome type II and Gilbert's syndrome. Material and methods. Clinical observation of a patient G. aged 19, who was examined and treated at the Department of gastroenterology of a multidisciplinary hospital in Moscow in January 2021. Results. The patient G. has had icteric sclerae and skin since birth; he occasionally suffers from easy fatigability and general malaise. Physical examination revealed no changes (except for icteric discoloration). An increase in unconjugated bilirubin up to 270 μmol/L (median - 170 μmol/L) was detected. The molecular genetic study of UGT1A1 gene identified mutations in exon 4 Val378Asp (2002) and Arg108Cys as well as polymorphism 6/7TA in the promoter region, confirming the diagnosis of autosomal recessive inherited disease – a combination of Crigler Najjar syndrome type II and Gilbert's syndrome (heterozygous state), complicated by the development of hepatic encephalopathy stage 2. There was noted a significant decrease in unconjugated bilirubin up to 170.5 μmol/L, as well as improvement in general condition – reduced fatigue and weakness during the treatment with microsomal enzyme inducer (phenobarbital) and hyperammonemia corrector (ornithine aspartate). Conclusions. The use of molecular genetic analysis allows tailoring strategies for patient-specific disease diagnostics, treatment and prevention. The preservation of quality of life within satisfactory level is achieved through elimination of adverse effects provoking the development of this syndrome and through control of risk factors.

29 December 2020 in Almanac of Clinical Medicine
Verified
Journal Article
Open access
PDF file
INIGOR G. NIKITIN
IGOR G. NIKITIN
LILyudmila Yu. Ilchenko
Lyudmila Yu. Ilchenko
IFI. G. Fedorov
I. G. Fedorov
GTG. G. Totolyan
G. G. Totolyan
COVID-19 (coronavirus disease 2019, a disease caused by a new coronavirus 2019) continues to threaten world public healthcare. Epidemiological data indicate that patients with metabolic disorders and chronic illnesses are most susceptible to SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2). Potential factors for organ involvement include systemic hyperimmune-mediated inflammation due to the “cytokine storm”, cytopathic effects, hypoxia, drug toxicities, etc. In addition, SARS-CoV-2, by interaction with ACE2 (angiotensin-converting enzyme 2) receptors in the vasculature endothelium results in endothelial dysfunction, increased permeability, microcirculatory abnormalities, vascular thrombophilia and thrombus formation. The diagnosis of COVID-19 is confirmed by detection of SARS-CoV-2 RNA in biological samples and serum antibodies. The infection is associated with leukopenia and thrombocytopenia, increased С-reactive protein, ferritin, lactate dehydrogenase, and D-dimer. Abnormalities in functional liver tests seen in COVID-19 are associated with progression and severity of the infection. The mechanism of direct cytotoxicity due to active SARS-CoV-2 replication in hepatocytes are not fully understood and is likely to be related to potential proliferation of hepatocytes, liver injury in response to systemic inflammation, and development of drug hepatic toxicity. We present a clinical case of drug-induced hepatitis in a patient with COVID-19 treated with tocilizumab, an inhibitor of interleukin 6 receptors. Prolonged increase in blood enzymes after treatment cessation is likely related to a longer half-elimination time of tocilizumab, which affects the oxidation-reduction system of liver cytochromes. Patients with chronic liver disorders are more vulnerable to clinical sequelae of СOVID-19, while the infection is frequently associated with hypoxia and hypoxemia due to severe pneumonia or the “cytokine storm”. In addition, patients who have been diagnosed with liver cirrhosis are at high risk of morbidity and mortality due to their higher proneness to infections, first of all, due to systemic immune deficiency that was demonstrated in the second clinical case. Decompensated liver cirrhosis is related not only to a higher risk of more severe COVID-19, but also to progression of chronic liver disease as such. To achieve effective results of causal and nosotropic therapy for COVID-19, it is highly significant to provide thorough clinical monitoring, tailored approach to the treatment of each patient with consideration of their comorbidities, immune status, and drug interactions.

23 December 2021 in Experimental and Clinical Gastroenterology
Verified
Journal Article
Open access
PDF file
LILyudmila Yu. Ilchenko
Lyudmila Yu. Ilchenko
IFI. G. Fedorov
I. G. Fedorov
GTG. G. Totolyan
G. G. Totolyan
AKA. M. Karelina
A. M. Karelina
GSG. A. Sedova
G. A. Sedova
INIGOR G. NIKITIN
IGOR G. NIKITIN
The article presents clinical case of the jaundice development and severe hyperenzymemia in GAM-Covid-VAK (Sputnik V) vaccination against COVID-19 in a 69-year-old patient. History — systematic use of non-steroidal anti-inflammatory drugs due to persisting pain after knee arthroplasty in 2018; frequent trips for several years to another region for sanatorium treatment, the use of mineral water. The diseases caused by hepatitis viruses, drug damage and post-vaccination reaction were included in diagnostic search. The markers of hepatitis B and C infection viruses were not detected during the enzyme immunoassay and polymerase chain reaction. The indicator for determining the relationship of a drug with the liver damage development was 6 points (borderline value) and only indicated the likelihood of drug hepatotoxicity. At the same time, it is known from history that repeated administration of the drug did not cause liver dysfunctions. The diagnosis of coronavirus infection was established based on the identification of SARS-CoV-2 in the hospital with repeated laboratory testing and competing diagnosis of hepatitis A has been confirmed on the basis of hepatocellular damage and the presence of serological marker of hepatitis A virus (immunoglobulin M antibodies). The treatment was continued in the infectious hospital, where the diagnosis of co-infection was confirmed. The pneumofibrotic changes in the S5 region of the left lung were revealed according to computed tomography. The normalization of aminotransferase activity and bilirubin was noted during dynamic observation. Apparently HAV infection led to a decrease in the immune response, the formation of an insufficient level of neutralizing antibodies in vaccinated against COVID-19 patient M. and contributed to the development of a new coronavirus infection with minimal manifestations in contact with SARS-CoV-2.

3 January 2023 in Russian Medicine
Verified
Journal Article
Open access
PDF file
AAAmina M. Alieva
Amina M. Alieva
NTNatalia V. Teplova
Natalia V. Teplova
ERElena Reznik
Elena Reznik
IBIrina E. Baykova
Irina E. Baykova
LSLidiya M. Shnakhova
Lidiya M. Shnakhova
ТГТотолян Гаяне Гургеновна
Тотолян Гаяне Гургеновна
Identification of a new significant level of regulation of gene activity using small non-coding molecules of ribonucleic acid miRNA can be confidently considered as one of the most outstanding discoveries of modern science It became clear that the suppression of gene expression caused by miRNA is an extremely important universal mechanism widely involved in most intracellular signaling pathways. Current data on the role of miRNA-122 in the development of cardiovascular diseases is included in this review. miRNA-122 is positioned as a promising biological marker in cardiovascular pathology. miRNA-122 promotes inflammation, oxidative stress, and apoptosis in cardiovascular disease. Clinical and experimental studies support the pathophysiological role of miRNA-122 in fibrosis and cardiac dysfunction. Overexpression of miRNA-122 exacerbates the loss of autophagy and enhances angiotensin II-mediated inflammation, apoptosis, fibrosis, and cardiac dysfunction. miRNA-122 should be considered not only as a promising diagnostic and prognostic tool, but also as a target for modern medicine. Inhibition of miRNA-122 results in antifibrotic, antiapoptotic, anti-inflammatory, antioxidant, and pro-autophagic effects. Further study is required to evaluate the real diagnostic and therapeutic potential of miRNA-122.

27 January 2021 in The Russian Archives of Internal Medicine
Verified
Journal Article
Open access
PDF file
EKE. Yu. Kudashkina
E. Yu. Kudashkina
EGE. G. Gavrilenko
E. G. Gavrilenko
AYA. A. Yakushev
A. A. Yakushev
GTG. G. Totolyan
G. G. Totolyan
NPN. N. Petrenko
N. N. Petrenko
INIGOR G. NIKITIN
IGOR G. NIKITIN
Primary hyperparathyroidism is a common pathology, but it is fact that doctors of various specialties run against difficulties in diagnosinging. The variety of clinical manifestations causes a long period of diagnosis and, late start of treatment. The main symptoms of this pathology are described taking into account the pathogenesis. The most common laboratory markers of hyperparathyroidism are incrising level of parathyroid hormone and hypercalcemia. Imaging examination methods are used to establish primary hyperparathyroidism. Targeted ultrasound examination of the parathyroid glands should be performed in all patients with suspected calcium metabolism disorders.This article presents a clinical case of primary hyperparathyroidism with predominant gastrointestinal symptoms. The patient was twice admitted to the hospital with various clinical manifestations of damage to the gastrointestinal tract. Erosive gastritis, terminal ileitis, chronic pancreatitis, and cholelithiasis were identified. A differential diagnosis was made with small intestine lymphoma and Crohn’s disease. In addition, there were General cerebral symptoms in the form of lethargy, rapid exhaustion. Due to severe electrolyte disorders, the patient was observed in the intensive care unit. Due to the development of mechanical jaundice, endoscopic retrograde cholangiopancreatography with papillosphincterotomy was performed. Based on hypercalcemia, elevated parathyroid hormone levels, and visualization of parathyroid gland formation, the diagnosis of primary hyperparathyroidism was established based on ultrasound data. An adenomectomy of the left lower parathyroid gland was performed. in the surgical department. The patient was discharged with positive dynamics in the form of improvement in General health, cessation of pain, regress of vomiting, expansion of motor activity. Betimes diagnosis and treatment of primary hyperparathyroidism, on the example of the described case, leads to complete relief of symptoms and improvement of the quality of life of patients.

15 January 2023 in Consilium Medicum
Verified
Journal Article
Open access
PDF file
AAAmina M. Alieva
Amina M. Alieva
ERElena Reznik
Elena Reznik
IBIrina E. Baykova
Irina E. Baykova
NTNatalia V. Teplova
Natalia V. Teplova
LMLiudmila M. Makeeva
Liudmila M. Makeeva
ТГТотолян Гаяне Гургеновна
Тотолян Гаяне Гургеновна
In recent years, the attention of scientists has been actively focused on studying the role of endocan as a biological marker of endothelial dysfunction in cardiovascular diseases. Until recent years, endocan has been studied in acute kidney injury, chronic kidney disease, and renal replacement therapy. Endocan, formerly known as endothelial cell-specific molecule-1, is a soluble dermatan sulfate proteoglycan expressed and secreted into the circulation from endothelial cells. Currently available studies demonstrate the diagnostic and prognostic value of endocan evaluation in cardiovascular pathology. It is expected that further scientific and clinical studies will demonstrate the possibilities of using endocan as an additional laboratory tool for diagnosing and assessing the prognosis in patients with a cardiac profile. Drug regulation of endocan concentration and expression may be a promising target for the treatment of cardiac and vascular pathology.